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Objective: The present study aimed to evaluate the biochemical markers of bone turnover in children with congenital hypothyroidism 
during the course of treatment as compared to healthy children selected as controls.
Methods: The study included 31 children with congenital hypothyroidism and 29 healthy children. In both groups, we evaluated serum 
procollagen type-1 N-terminal propeptide (PINP) and tartrate-resistant acid phosphatase type 5b isoform (TRACP 5b) levels as bone 
turnover markers. 
Results: In both groups, thyroid hormone levels were within normal limits. The levels of vitamin D were significantly higher in the cases 
with congenital hypothyroidism. Although PINP levels were not found to be different, TRACP 5b levels which are related to osteoclastic 
activities were significantly higher in the control group. 
Conclusion: We did not detect an increase in bone resorption in patients with congenital hypothyroidism, despite long-term treatment 
with LT4. Our results suggest that with effective vitamin D treatment and thyroxin replacement, congenital hypothyroidism is not a 
deleterious factor for bone turnover. 
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Introduction
Congenital hypothyroidism (CH) is one of the most common 
preventable causes of intellectual disability (1). Effects of 
hypothyroidism have decreased in babies administered 
treatment in accordance with the neonatal screening 
program (2). Untreated CH results in delayed bone age, 
growth retardation, and short stature (3).
Thyroid hormones also have important effects on the 
bone remodeling cycle. However, this effect has been 
shown to increase in favor of bone resorption, especially 
in thyrotoxicosis (4). In some studies in adults, long-
term treatment with levothyroxine has been reported to 
decrease bone density, which may result in bone fractures 
(4,5,6). In contrast, some studies have indicated that 
long-term treatment would not affect bone density (7,8). 
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What is already known on this topic?
What this study adds?
Long-term treatment with LT4 increases bone resorption in patients with congenital hypothyroidism.
Our results suggest that with effective vitamin D and thyroxin replacement, congenital hypothyroidism is not a deleterious factor for 
bone turnover.
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Both hypothyroidism and hyperthyroidism have been 
associated with an increased risk of fractures. It has been 
determined that remodeling increases in adults in the 
course of hypothyroidism; in this situation, osteoclastic 
duration is increased twofold, whereas osteoblastic duration 
is prolonged fourfold. These changes result in low bone 
turnover and an overall failure to gain bone mass and 
mineral (3).
In children diagnosed with CH in the neonatal period and 
treated for a long time, the bone remodeling cycle may 
indicate the effects of thyroid hormone treatment or those 
of CH. Additionally, the presence of vitamin D deficiency 
also affects the bone cycle (9). In the assessment of the 
bone cycle by serum analysis, the new bone formation 
may be evaluated by the level of serum procollagen type 1 
N-terminal propeptide (PINP), and bone resorption by the 
level of the enzyme tartrate-resistant acid phosphatase type 
5b isoform (TRACP 5b), which is secreted by osteoclasts 
(10). The present study aimed to evaluate the biochemical 
markers of bone turnover in children with CH who had been 
followed up during the course of treatment and in healthy 
children selected as controls. 
Methods 
The study included 31 children with CH followed up by 
the Başkent University, School of Medicine, Pediatric 
Endocrinology outpatient clinic and 29 healthy children 
followed up by the General Pediatrics outpatient clinic. All 
patients and their families were informed about the study, 
and consent was obtained from the families. Blood samples 
were withdrawn during the blood sampling for medical 
purposes. 
Of the 31 patients with CH, 14 were cases of hypoplastic 
thyroid gland, one had agenesis, one had an ectopic thyroid 
gland, 14 had thyroid dyshormonogenesis, and one had a 
fetal goiter related to the TPO gene mutation. The initial LT4 
treatment was administered at a dose of 7.5-15 µg/kg/day 
during the neonatal period. 
The cases in the control group (n=29) were selected from 
those who had been followed up by the General Pediatrics 
outpatient clinic and had no chronic disease or abnormal 
neonatal screening result. They were not taking any 
medication. We did not question the dosage and duration of 
vitamin D intake in the two groups. 
Chronological age, weight, height, and percent of ideal weight 
for height were evaluated in all patients. All blood samples 
were withdrawn in the morning, at the same time. The 
serum levels of calcium, phosphorus, alkaline phosphatase 
(ALP), magnesium, thyroid-stimulating hormone (TSH), 
free thyroxine (fT4), parathyroid hormone (PTH), 25 
hydroxycholecalciferol [25(OH)D3-Vitamin D], PINP, TRACP 
5b, and urine calcium/creatinine ratio were analyzed in the 
biochemistry laboratory of Başkent University. 
CH and control groups were compared according to vitamin 
D status, deficient or non-deficient. 
Venous blood samples were drawn and sera were stored 
at -20 οC after centrifugation until testing. All assays 
were carried out at the same time. The levels of 25(OH)
D were assayed using chemiluminescent microparticle 
immunoassay (Abbott Architect I2000 analyzer). The 
architect 25(OH)D assay is designed to have a limit of 
detection (LoD) of ≤10.0 ng/mL. Serum levels of calcium, 
phosphorus, ALP, magnesium, TSH, and fT4 were measured 
in the blood cell counter using an Abbott Cell-Dyn Ruby 
System (Abbott Diagnostic, Santa Clara, CA, USA). 
Vitamin D levels at or below 15 ng/mL were defined as 
vitamin D deficiency (9).
PINP was measured by kit which is a sandwich enzyme 
immunoassay for in vitro quantitative measurement of PINP 
in human serum incubated for 30 minutes at 37 oC after 
covering it with the Plate sealer. The minimum detectable 
dose of PINP is typically less than 6.2 pg/mL. The intra- and 
inter-assay coefficients of variation (CV) reported by the 
manufacturer are <10% and <12% (Uscn Life Science Inc. 
Wuhan, Hubei, PRC). 
TRACP was assayed by an immunoCapture Enzyme-Activity 
Assay in serum (BioVendor Research and Diagnostic 
Products, Czech Republic). In the BioVendor Human TRAP 5 
Assay, calibrators, quality control and samples are incubated 
in microplate wells pre-coated with monoclonal anti-human 
TRAP 5 antibody. After a thorough wash, TRACP 5b bound 
to the antibody is allowed to react with the pNPP substrate 
at pH 5.5. The reaction is stopped by addition of hydroxine 
solution and absorbance of the resulting yellow color 
product is measured. The absorbance is proportional to 
the enzymatic activity of TRACP 5b. A calibration curve is 
constructed by plotting absorbance values against enzyme 
activities of recombinant TRACP 5 calibrators, and enzyme 
activity of unknown samples are determined (U/I) using this 
calibration curve. LoD is calculated from the real TRAP 5 
values in wells and is 0.01 U/I. The intra- and inter-assay CVs 
reported by manufacturer are 2.4% and 7.6%.
This study was approved by the Başkent University 
Institutional Review Board and Ethics Committee (Project 
No: KA12/46) and supported by the Başkent University 
Research Fund.
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Statistical Analysis
Data were analyzed using the SPSS 20 (IBM Corp. Released 
2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, 
NY: IBM Corp.) statistical software. Values were expressed as 
mean ± standard deviation, median (maximum-minimum), 
percentage, and frequency. Variables were evaluated after 
controlling the normality and homogeneity of variance 
prerequisites (Shapiro-Wilk and Levene’s tests). Data were 
compared between the two groups using the independent 
t-test (Student’s t-test); the Mann-Whitney U-test was used in 
the absence of prerequisites. Categorical data were analyzed 
using the Fisher’s exact test and chi-square test. When the 
expected frequencies were lower than 20%, evaluation by 
the “Monte Carlo simulation method” was performed in 
order to include these frequencies in the analysis. A p-value 
<0.05 was accepted as statistically significant. 
Results
The characteristics of the cases with CH and control subjects 
are presented in Table 1. The values of chronological age, 
height-for-age, body weight, height, and percent of ideal 
weight for height were not different in the CH and control 
groups. Laboratory results on serum calcium, phosphorus, 
magnesium, ALP, fT4, TSH, PTH, and PINP levels were also 
not statistically different from one another and were also in 
the normal range. Mean TRACP 5b levels were significantly 
higher in the control group. The levels of vitamin D were 
significantly higher in the cases with CH (Table 1).
According to vitamin D status, TRACP 5b levels were 
significantly higher in controls. PINP levels were not found 
to be different (Table 2).
Discussion
The acid phosphatases are lysosomal enzymes, and the 
isoform 5b secreted from the osteoclasts is a marker used to 
detect bone resorption. On the other hand, procollagen type 
1 N-terminal propeptide is a marker used for the evaluation 
of bone formation (11). In the present study, bone turnover 
was evaluated in children with and without CH. 
Bone is a metabolically active tissue that undergoes 
continuous remodeling throughout life. In the course of 
bone remodeling, bone resorption is closely associated 
with new bone formation. Bone resorption and formation 
can be affected by some diseases and this process may 
be evaluated by the serum levels of several markers (10). 
The effect of congenital non-goiter hypothyroidism on 
bone is still not completely understood (12). Population 
studies have demonstrated that both hypothyroidism and 
hyperthyroidism affect bone remodeling and that they may 
increase the risk of bone fractures. Studies conducted on 
mice have shown that TSH affects the bone remodeling cycle 
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Table 1. The characteristics of the cases with congenital hypothyroidism and the controls 
n Congenital 
hypothyroidism
n Controls p-values
Male/Female 31 21/11 28 17/11 0.091
Age (years) 31 4.02±2.00 28 4.05±1.45 0.961
Body weight (kilograms) 31 17.56±6.45 28 16.36±3.06 0.373
Height (cm) 31 101.65±10.55 28 104.96±12.47 0.399
Biochemistry
Calcium (mg/dL) 31 9.89±0.40 28 9.72±0.31 0.075
Phosphorus (mg/dL) 31 5.12±0.35 28 4.71±0.54 0.082
Alkaline phosphatase (U/L) 31 196.38±43.06 28 238.11±28.75 0.442
25-OH-Vit D (ng/mL) 29 29.22±10.54 28 20.87±7.02 0.001*
PINP    (pg/mL) 31 16.82±2.21 28 17.83±7.90 0.499
TRACP 5b  (U/L) 31 1.88±0.55 28 8.79±0.40 0.001*
TSH    (µIU/mL) 31 2.24±2.51 27 1.79±0.94 0.079
fT4 (ng/dL) 31 1.26±0.19 27 1.18±0.14 0.070
PTH (pg/mL) 27 35.11±2.98 21 23.13±4.38 0.024
Magnesium (mg/dL) 22 2.09±0.12 28 2.07±0.13 0.957
Urine Ca/Cre 20 0.14±0.04 18 0.14±0.03 0.934
TRACP 5b: tartrate-resistant acid phosphatase type 5b, PINP: procollagen type-1 N-terminal propeptide, PTH: parathyroid hormone, fT4: free thyroxine,  
TSH: thyroid-stimulating hormone, Ca/Cre: calcium/creatinine ratio, 25-OH-Vit D: 25 hydroxycholecalciferol Vitamin D
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negatively (4,5,6,7,8). Papadimitriou et al (13) determined 
that the low levels of TSH do not lead to bone loss in mice. 
In our study, TSH and fT4 levels were found to be similar in 
the hypothyroid and control groups, but the level of TRACP 
5b, which is an indicator of bone resorption, was found to 
be lower in the hypothyroid group; in other words, bone 
resorption was low in hypothyroid cases.
Engler et al (14) showed that the thyroid hormones also 
affect bone turnover. In this study, the values indicating bone 
resorption were high in the cases with hyperthyroidism, 
before the administration of anti-thyroid treatment. 
In several studies conducted on adults, TSH was reported 
to be suppressed by the administration of LT4 in patients 
with thyroid cancer and non-toxic goiter who did not have 
thyrotoxicosis, and bone density was reported to be decreased 
(4,5,6). In contrast to these results, Franklyn et al (7) and 
Marcocci et al (8) did not detect any change in bone density 
following treatment with LT4 for as long as 8 to 10 years. Leger 
et al (4) did not detect a change in bone mineral density in 
favor of bone resorption, in patients undergoing long-term 
LT4 treatment. Similarly, in our study, any effect on bone 
resorption has not been demonstrated in the group with CH. 
Vitamin D contributes to bone turnover, and it is used as 
a supportive treatment, starting in infancy. We determined 
the level of vitamin D to be significantly higher in children 
with CH. When the cases were subdivided according to their 
vitamin D levels, TRACP 5b levels were found to be higher 
in the controls in both vitamin D sufficiency and deficiency 
situations. The value of PINP, which indicates the formation 
of new bone, did not differ significantly between the groups. 
In this study, we did not detect an increase in bone resorption 
in patients followed up in our clinic. The children with CH 
might have received more effective vitamin D replacement 
due to their close and more frequent follow-ups. The mean 
duration of follow-up in our hypothyroid patients was four 
years which may be considered as one of the limitations 
of the study. We did not question the duration and dose of 
vitamin D intake in the CH and control groups which is the 
other limitation. 
Reference values for TRACP 5b have been published for 
Chinese in 2005 and subsequently for Caucasian children, 
in 2007 and 2012 (15,16,17). Rauchenzauner et al (16) has 
reported the TRACP 5b values for 50th percentile as 8.1 U/L 
for boys and 6.8 for girls in the 0-18 age group. Fischer et al 
Table 2. Comparison of the two groups according to vitamin D status
         Vitamin D levels: 0 to 14.99 ng/mL        Vitamin D levels: ≥15 ng/mL
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Age (Years) 2 4.95±1.91 5 4.29±1.59 0.655 27 3.90±2.08 23 3.99±1.45 0.874
Height (cm) 2 110.5±7.07 5 108.4±8.2 0.766 27 101.13±17.7 23 104.2±13.2 0.497
Body weight (kg) 2 18.95±0.49 5 16.88±2.72 0.357 27 17.5±6.8 23 16.2±3.1 0.402
Percent of ideal 
weight for height
2 102.7±8.8 5 99.5±7.37 0.641 27 101.6±10.7 23 95.9±11.5 0.057
Calcium (mg/dL) 2 9.65±0.78 5 9.56±0.19 0.793 27 9.91±0.39 23 9.75±0.31 0.109
Phosphorus
(mg/dL)
2 5.1±0.57 5 4.84±0.52 0.584 27 5.11±0.35 23 4.88±0.55 0.065
ALP (U/L) 2 150.5±2.12 5 190.4±26.7 0.414 27 200.2±8.5 23 248.4±65 0.44
PINP (pg/mL) 2 18.25±1.12 5 27.1±7.34 0.503 27 16.73±2.33 23 15.8±1.94 0.136
TRACP 5b (U/L) 2 0.63±0.09 5 9.98±1.21 0.001* 27 1.78±0.58 23 8.5±2.17 0.001*
TSH (µIU/mL) 2 2.35±4.45 5 1.38±0.22 0.073 27 2.12±2.5 22 1.88±0.99 0.081
fT4 (ng/dL) 2 1.35±0.07 5 1.25±0.13 0.356 27 1.21±1.19 22 1.16±0.14 0.09
PTH (pg/mL) 2 49.25±24.35 4 31.3±10.01 0.062 24 34.57±13.81 17 26.79±4.60 0.145
Magnesium
(mg/dL)
2 2.02±0.02 5 1.95±0.13 0.867 20 2.10±0.12 23 2.08±0.01 0.923
Urine Ca/cre 1 0.31 4 0.12±0.05 - 18 0.138±0.039 14 0.146±0.039 0.887
ALP: alkaline phosphatase, TRACP 5b: tartrate-resistant acid phosphatase type 5b, PINP: procollagen type-1 N-terminal propeptide, PTH: parathyroid hormone, 
fT4: free thyroxine, TSH: thyroid-stimulating hormone, Ca/Cre: calcium/creatinine ratio
110
Karakaş NM et al. 
Congenital Hypothyroidism and Bone
J Clin Res Pediatr Endocrinol
2017;9(2):106-110
(17) determined the TRACP 5b values for 50th percentile at 
age 4 years to be 13.8 U/L for boys and 17 U/L for girls (17). 
The distribution of normal TRACP levels showed a wide 
range, depending on age, sex, and pubertal stage. Vitamin 
D levels were not given in the above studies. 
Our study included an age-matched healthy prepubertal 
control group. We measured the vitamin D levels in both 
groups. We speculate that the main reason for the higher 
TRACP 5b levels in the controls might be the lower vitamin 
D levels.
In conclusion, we did not detect an increase in bone 
resorption in patients with CH, despite long-term treatment 
with LT4. Our results suggest that with effective vitamin D 
and thyroxin replacement, CH is not a deleterious factor for 
bone turnover. 
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